The drug is a joint venture between Bayer Healthcare Phamaceuticals and Johnson & Johnson. Johnson & Johnson has applied for approval for short-term use of the drug in the prevention of deep-vein thrombosis and pulmonary embolism in patients undergoing total hip and knee replacement surgery.
The company has recently finished clinical trials on the longer-term use of rivaroxaban in patients with acute coronary syndrome.
Read about the FDA panel’s recommendation to approve rivaroxaban.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
